Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Cash & Equivalents (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Cash & Equivalents data on record, last reported at $6.7 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 28.73% year-over-year to $6.7 million; the TTM value through Sep 2025 reached $6.7 million, down 28.73%, while the annual FY2024 figure was $4.3 million, 81.83% down from the prior year.
  • Cash & Equivalents reached $6.7 million in Q3 2025 per MBRX's latest filing, down from $7.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $86.3 million in Q1 2021 and bottomed at $4.3 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $37.4 million, with a median of $32.2 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 640.78% in 2021, then crashed 81.83% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $70.9 million in 2021, then plummeted by 39.15% to $43.1 million in 2022, then tumbled by 45.42% to $23.6 million in 2023, then plummeted by 81.83% to $4.3 million in 2024, then soared by 56.69% to $6.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $6.7 million in Q3 2025, $7.6 million in Q2 2025, and $7.7 million in Q1 2025.